<?xml version='1.0' encoding='utf-8'?>
<document id="20352154"><sentence text="The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response."><entity charOffset="11-21" id="DDI-PubMed.20352154.s1.e0" text="amlodipine" /><entity charOffset="60-67" id="DDI-PubMed.20352154.s1.e1" text="calcium" /><entity charOffset="104-115" id="DDI-PubMed.20352154.s1.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.20352154.s1.e0" e2="DDI-PubMed.20352154.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s1.e0" e2="DDI-PubMed.20352154.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s1.e0" e2="DDI-PubMed.20352154.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s1.e1" e2="DDI-PubMed.20352154.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s1.e1" e2="DDI-PubMed.20352154.s1.e2" /></sentence><sentence text="Clopidogrel is a prodrug that has to be converted in vivo to its active metabolite by cytochrome (CYP)P450 iso-enzymes"><entity charOffset="0-11" id="DDI-PubMed.20352154.s2.e0" text="Clopidogrel" /></sentence><sentence text=" As calcium channel blockers (CCBs) are inhibitors of CYP3A4, concomitant use of these drugs might play a role in the wide inter-individual variability in the response to clopidogrel"><entity charOffset="4-11" id="DDI-PubMed.20352154.s3.e0" text="calcium" /><entity charOffset="171-182" id="DDI-PubMed.20352154.s3.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.20352154.s3.e0" e2="DDI-PubMed.20352154.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s3.e0" e2="DDI-PubMed.20352154.s3.e1" /></sentence><sentence text=" However, some CCBs also have strong inhibitory effects on the drug transporter P-glycoprotein (Pgp), which mediates clopidogrel's intestinal absorption" /><sentence text=" It was the aim of this study to evaluate the effect of co-administration of Pgp-inhibiting and non-Pgp-inhibiting CCBs on on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective percutaneous coronary intervention (PCI)"><entity charOffset="126-137" id="DDI-PubMed.20352154.s5.e0" text="clopidogrel" /></sentence><sentence text=" In a total of 623 consecutive patients undergoing elective PCI treated with clopidogrel and aspirin, platelet reactivity to 5 and 20 muM adenosine diphospate (ADP) and clopidogrel poor-response (defined as &gt; 70% platelet aggregation to 20 muM ADP) were evaluated by light transmittance aggregometry"><entity charOffset="77-88" id="DDI-PubMed.20352154.s6.e0" text="clopidogrel" /><entity charOffset="93-100" id="DDI-PubMed.20352154.s6.e1" text="aspirin" /><entity charOffset="138-158" id="DDI-PubMed.20352154.s6.e2" text="adenosine diphospate" /><entity charOffset="160-163" id="DDI-PubMed.20352154.s6.e3" text="ADP" /><entity charOffset="169-180" id="DDI-PubMed.20352154.s6.e4" text="clopidogrel" /><entity charOffset="244-254" id="DDI-PubMed.20352154.s6.e5" text="ADP" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e0" e2="DDI-PubMed.20352154.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e0" e2="DDI-PubMed.20352154.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e0" e2="DDI-PubMed.20352154.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e0" e2="DDI-PubMed.20352154.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e0" e2="DDI-PubMed.20352154.s6.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e0" e2="DDI-PubMed.20352154.s6.e5" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e1" e2="DDI-PubMed.20352154.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e1" e2="DDI-PubMed.20352154.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e1" e2="DDI-PubMed.20352154.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e1" e2="DDI-PubMed.20352154.s6.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e1" e2="DDI-PubMed.20352154.s6.e5" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e2" e2="DDI-PubMed.20352154.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e2" e2="DDI-PubMed.20352154.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e2" e2="DDI-PubMed.20352154.s6.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e2" e2="DDI-PubMed.20352154.s6.e5" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e3" e2="DDI-PubMed.20352154.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e3" e2="DDI-PubMed.20352154.s6.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e3" e2="DDI-PubMed.20352154.s6.e5" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e4" e2="DDI-PubMed.20352154.s6.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s6.e4" e2="DDI-PubMed.20352154.s6.e5" /></sentence><sentence text=" A total of 222 patients (35" /><sentence text="6%) were on CCB treatment, of which 98 used Pgp-inhibiting CCBs (verapamil, nifedipine, diltiazem, barnidipine) and 124 patients used the non-Pgp-inhibiting CCB amlodipine"><entity charOffset="65-74" id="DDI-PubMed.20352154.s8.e0" text="verapamil" /><entity charOffset="76-86" id="DDI-PubMed.20352154.s8.e1" text="nifedipine" /><entity charOffset="88-97" id="DDI-PubMed.20352154.s8.e2" text="diltiazem" /><entity charOffset="99-110" id="DDI-PubMed.20352154.s8.e3" text="barnidipine" /><entity charOffset="161-171" id="DDI-PubMed.20352154.s8.e4" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e0" e2="DDI-PubMed.20352154.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e0" e2="DDI-PubMed.20352154.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e0" e2="DDI-PubMed.20352154.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e0" e2="DDI-PubMed.20352154.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e0" e2="DDI-PubMed.20352154.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e1" e2="DDI-PubMed.20352154.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e1" e2="DDI-PubMed.20352154.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e1" e2="DDI-PubMed.20352154.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e1" e2="DDI-PubMed.20352154.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e2" e2="DDI-PubMed.20352154.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e2" e2="DDI-PubMed.20352154.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e2" e2="DDI-PubMed.20352154.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e3" e2="DDI-PubMed.20352154.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20352154.s8.e3" e2="DDI-PubMed.20352154.s8.e4" /></sentence><sentence text=" Adjusted mean ADP-induced on-clopidogrel platelet reactivity was significantly higher in both users of Pgp-inhibiting CCBs and amlodipine as compared to CCB non-users (all p&lt;0"><entity charOffset="30-41" id="DDI-PubMed.20352154.s9.e0" text="clopidogrel" /><entity charOffset="128-138" id="DDI-PubMed.20352154.s9.e1" text="amlodipine" /><entity charOffset="15-24" id="DDI-PubMed.20352154.s9.e2" text="ADP" /><pair ddi="false" e1="DDI-PubMed.20352154.s9.e2" e2="DDI-PubMed.20352154.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20352154.s9.e2" e2="DDI-PubMed.20352154.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s9.e2" e2="DDI-PubMed.20352154.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20352154.s9.e0" e2="DDI-PubMed.20352154.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s9.e0" e2="DDI-PubMed.20352154.s9.e1" /></sentence><sentence text="05)" /><sentence text=" However, only the use of amlodipine was significantly associated with a 2"><entity charOffset="26-36" id="DDI-PubMed.20352154.s11.e0" text="amlodipine" /></sentence><sentence text="3-fold increased risk of clopidogrel poor-response"><entity charOffset="25-36" id="DDI-PubMed.20352154.s12.e0" text="clopidogrel" /></sentence><sentence text=" This study demonstrates that concomitant use of Pgp-inhibiting CCBs and amlodipine increases on-clopidogrel platelet reactivity"><entity charOffset="73-83" id="DDI-PubMed.20352154.s13.e0" text="amlodipine" /><entity charOffset="97-108" id="DDI-PubMed.20352154.s13.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.20352154.s13.e0" e2="DDI-PubMed.20352154.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s13.e0" e2="DDI-PubMed.20352154.s13.e1" /></sentence><sentence text=" Only amlodipine was associated with clopidogrel poor-response"><entity charOffset="6-16" id="DDI-PubMed.20352154.s14.e0" text="amlodipine" /><entity charOffset="37-48" id="DDI-PubMed.20352154.s14.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.20352154.s14.e0" e2="DDI-PubMed.20352154.s14.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s14.e0" e2="DDI-PubMed.20352154.s14.e1" /></sentence><sentence text=" The drug-drug interaction between clopidogrel and amlodipine might be more clinically relevant as compared to P-glycoprotein-inhibiting CCBs"><entity charOffset="35-46" id="DDI-PubMed.20352154.s15.e0" text="clopidogrel" /><entity charOffset="51-61" id="DDI-PubMed.20352154.s15.e1" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.20352154.s15.e0" e2="DDI-PubMed.20352154.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20352154.s15.e0" e2="DDI-PubMed.20352154.s15.e1" /></sentence><sentence text="" /></document>